BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.09
+1.46% today
Updated 2026-04-30
Market cap
$5.37M
P/E ratio
—
P/S ratio
0.72x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
BioNexus Gene Lab Corp Common stock (BGLC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-80.8%
Most recent quarter
EPS YoY growth
-169.7%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+1.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+3.5%
2025-11-14
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.52 | — | $3.95 | $3.94 | -0.3% |
| 2025-11-14 | $-0.40 | — | $4.52 | $4.68 | +3.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | — | $-0.52 | — | $483760.00 | -80.8% |
| 2025-09-30 | — | $-0.40 | — | $2.54M | -3.3% |
| 2025-06-30 | $0.00 | $-0.34 | — | $2.26M | +14.5% |
| 2025-03-31 | — | $-0.19 | — | $2.14M | -10.3% |
| 2024-12-31 | — | $-0.19 | — | $2.52M | +11.0% |
| 2024-09-30 | — | $-0.75 | — | $2.63M | +3.0% |
| 2024-06-30 | — | $0.11 | — | $1.97M | -23.1% |
| 2024-03-31 | — | $-0.06 | — | $2.38M | — |
| 2023-12-31 | — | $0.17 | — | $2.27M | — |
| 2023-09-30 | — | $-1.56 | — | $2.55M | — |
| 2023-06-30 | — | $-0.18 | — | $2.57M | — |
| 2023-03-31 | — | $-0.05 | — | — | — |
Frequently asked questions
Has BioNexus Gene Lab Corp Common stock beaten earnings estimates?
BioNexus Gene Lab Corp Common stock has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports.
How does BGLC stock react to earnings?
BGLC stock has moved an average of +1.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is BioNexus Gene Lab Corp Common stock's revenue growth rate?
BioNexus Gene Lab Corp Common stock reported year-over-year revenue growth of -80.8% in its most recent quarter, with EPS growing -169.7% year-over-year.